Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed the stock exchanges that its subsidiary Optival Health Solutions Private Limited received two drug license suspension orders from the Drugs Control Administration in Warangal, Telangana. The first store at Station Ghanpur faces a 5-day suspension, while the second store at Girinigadda main road, Jangaon faces a 3-day suspension. The orders were received on July 30, 2025, and were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The estimated revenue loss is very small at approximately Rs 0.98 lakhs for the first store and Rs 0.40 lakhs for the second store, totalling around Rs 1.38 lakhs.
The financial impact is negligible at just Rs 1.38 lakhs combined, so this is unlikely to affect the stock price. It is a routine regulatory compliance disclosure involving minor store-level license issues with no material business impact.